Eija Nissilä

7PUBLICATIONS
18CO-AUTHORS
Immunogenetics (incl. genetic immunology)Cancer therapy (excl. chemotherapy and radiation therapy)Behavioural epidemiologyInnate immunityAllergy
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (7)

|Jul 07, 2025
The total gut mucosal and fecal bacterial load increases in successful treatment of inflammatory bowel disease with infliximab.

Rebecka Ventin-Holmberg, Julia Eriksson, Anja Eberl

|Jan 31, 2025
The COVID-19 vaccine ChAdOx1 is opsonized by anti-vector antibodies that activate complement and promote viral vector phagocytosis.

Eija Nissilä, Leo Starck, Elias Aho

|May 08, 2023
Reduced binding of apoE4 to complement factor H promotes amyloid-β oligomerization and neuroinflammation.

Larisa Chernyaeva, Giorgio Ratti, Laura Teirilä

|Aug 30, 2022
Quantitative Fecal Microbiota Profiles Relate to Therapy Response During Induction With Tumor Necrosis Factor α Antagonist Infliximab in Pediatric Inflammatory Bowel Disease.

Miikka Höyhtyä, Katri Korpela, Schahzad Saqib

|Dec 10, 2020
Bacterial and Fungal Profiles as Markers of Infliximab Drug Response in Inflammatory Bowel Disease.

Rebecka Ventin-Holmberg, Anja Eberl, Schahzad Saqib

|Aug 24, 2017
C4B gene influences intestinal microbiota through complement activation in patients with paediatric-onset inflammatory bowel disease.

E Nissilä, K Korpela, A I Lokki

Pageof 2

Frequent Collaborators

1 joint publications

Miikka Höyhtyä

1 joint publications

Giorgio Ratti

1 joint publications

Satoshi Fudo

1 joint publications

Uni Rankka